COST-EFFECTIVENESS OF RITUXIMAB-BASED CHEMOTHERAPY COMBINATIONS FOR THE INTIAL THERAPY OF FOLLICULAR LYMPHOMA

被引：0
|
作者：
Shah, G. [1 ]
Winn, A. [2 ]
Kumar, A. [3 ]
Lin, P. [3 ]
Parsons, S. [3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Univ North Carolina Chapel Hill, Chapel Hill, NC USA
[3] Tufts Med Ctr, Boston, MA USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY70
引用
收藏
页码：A221 / A221
页数：1
相关论文
共 50 条
  • [21] Cost-Effectiveness of Rituximab for Maintenance in Patients with Follicular Non-Hodgkin's Lymphoma in the Dutch Setting
    Pompen, Marjolein
    Huijgens, P. C.
    BLOOD, 2008, 112 (11) : 824 - 824
  • [22] The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma
    Prettyjohns, Matthew
    Hoskin, Peter
    McNamara, Christopher
    Linch, David
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (01) : 52 - 59
  • [23] Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular non-Hodgkin's lymphoma in Sweden
    Kasteng, F.
    Erlanson, M.
    Hagberg, H.
    Kimby, E.
    Relander, T.
    Lunckvist, J.
    VALUE IN HEALTH, 2007, 10 (06) : A331 - A331
  • [24] Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Folio First-Line Therapy in Patients with Follicular Lymphoma
    Chen, Qiushi
    Ayer, Turgay
    Nastoupil, Loretta J.
    Rose, Adam C.
    Flowers, Christopher R.
    VALUE IN HEALTH, 2015, 18 (02) : 189 - 197
  • [25] COST-EFFECTIVENESS OF DUVELISIB VERSUS THE BENDAMUSTINE PLUS RITUXIMAB REGIMEN FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA PATIENTS IN CHINA
    Chen, L.
    Tan, B.
    Gao, X.
    Zhou, K.
    Zhao, J.
    Xuan, J.
    VALUE IN HEALTH, 2023, 26 (12) : S181 - S182
  • [26] COST-EFFECTIVENESS OF RITUXIMAB IN FOLLICULAR LYMPHOMA FIRST LINE MAINTENANCE TREATMENT FROM PUBLIC PAYER PERSPECTIVE IN POLAND
    Gadaj, A.
    Kalinowska, A.
    Hawrylecka, D.
    Holojda, J.
    Krawcewicz, A.
    Spychalowicz, W.
    Russel-Szymczyk, M.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2011, 14 (07) : A449 - A450
  • [27] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Eliazar Sabater
    Armando López-Guillermo
    Antonio Rueda
    Antonio Salar
    Itziar Oyagüez
    Juan Manuel Collar
    Applied Health Economics and Health Policy, 2016, 14 : 465 - 477
  • [28] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Sabater, Eliazar
    Lopez-Guillermo, Armando
    Rueda, Antonio
    Salar, Antonio
    Oyaguez, Itziar
    Manuel Collar, Juan
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (04) : 465 - 477
  • [29] Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate-High Risk: A Cost-Effectiveness Analysis
    Bellone, Marco
    Pradelli, Lorenzo
    Molica, Stefano
    De Francesco, Adele Emanuela
    Ghislieri, Daniela
    Guardalben, Emanuele
    Caputo, Antonietta
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 661 - 671
  • [30] Prognostic value of baseline SUVmax in patients with advanced stage follicular lymphoma receiving frontline rituximab-based therapy.
    Strati, Paolo
    Ahmed, Mohamed Amin
    Fowler, Nathan Hale
    Hagemeister, Fredrick B.
    Fayad, Luis
    Rodriguez, Maria Alma
    Samaniego, Felipe
    Wang, Michael
    Westin, Jason
    Romaguera, Jorge Enrique
    Noorani, Mansoor
    Phansalkar, Karishma
    Cheah, Chan
    Feng, Lei
    Davis, Richard Eric
    Nastoupil, Loretta J.
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345